Targeting MYC through WDR5

The oncoprotein transcription factor MYC is overexpressed in most cancers and is responsible for hundreds of thousands of cancer deaths worldwide every year. MYC is also a highly validated – but currently undruggable – anti-cancer target. We recently showed that breaking the interaction of MYC with...

Descripción completa

Detalles Bibliográficos
Autores principales: Thomas, Lance R., Adams, Clare M., Fesik, Stephen W., Eischen, Christine M., Tansey, William P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Author's Views
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7051159/
https://www.ncbi.nlm.nih.gov/pubmed/32158922
http://dx.doi.org/10.1080/23723556.2019.1709388
_version_ 1783502722412052480
author Thomas, Lance R.
Adams, Clare M.
Fesik, Stephen W.
Eischen, Christine M.
Tansey, William P.
author_facet Thomas, Lance R.
Adams, Clare M.
Fesik, Stephen W.
Eischen, Christine M.
Tansey, William P.
author_sort Thomas, Lance R.
collection PubMed
description The oncoprotein transcription factor MYC is overexpressed in most cancers and is responsible for hundreds of thousands of cancer deaths worldwide every year. MYC is also a highly validated – but currently undruggable – anti-cancer target. We recently showed that breaking the interaction of MYC with its chromatin co-factor WD repeat-containing protein 5 (WDR5) promotes tumor regression in mouse xenografts, laying the foundation for a new strategy to inhibit MYC in the clinic.
format Online
Article
Text
id pubmed-7051159
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-70511592020-09-28 Targeting MYC through WDR5 Thomas, Lance R. Adams, Clare M. Fesik, Stephen W. Eischen, Christine M. Tansey, William P. Mol Cell Oncol Author's Views The oncoprotein transcription factor MYC is overexpressed in most cancers and is responsible for hundreds of thousands of cancer deaths worldwide every year. MYC is also a highly validated – but currently undruggable – anti-cancer target. We recently showed that breaking the interaction of MYC with its chromatin co-factor WD repeat-containing protein 5 (WDR5) promotes tumor regression in mouse xenografts, laying the foundation for a new strategy to inhibit MYC in the clinic. Taylor & Francis 2020-01-10 /pmc/articles/PMC7051159/ /pubmed/32158922 http://dx.doi.org/10.1080/23723556.2019.1709388 Text en © 2020 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
spellingShingle Author's Views
Thomas, Lance R.
Adams, Clare M.
Fesik, Stephen W.
Eischen, Christine M.
Tansey, William P.
Targeting MYC through WDR5
title Targeting MYC through WDR5
title_full Targeting MYC through WDR5
title_fullStr Targeting MYC through WDR5
title_full_unstemmed Targeting MYC through WDR5
title_short Targeting MYC through WDR5
title_sort targeting myc through wdr5
topic Author's Views
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7051159/
https://www.ncbi.nlm.nih.gov/pubmed/32158922
http://dx.doi.org/10.1080/23723556.2019.1709388
work_keys_str_mv AT thomaslancer targetingmycthroughwdr5
AT adamsclarem targetingmycthroughwdr5
AT fesikstephenw targetingmycthroughwdr5
AT eischenchristinem targetingmycthroughwdr5
AT tanseywilliamp targetingmycthroughwdr5

Ejemplares similares